C8Mab-3: An Anti-Mouse CCR8 Monoclonal Antibody for Immunocytochemistry.

Q3 Medicine Monoclonal Antibodies in Immunodiagnosis and Immunotherapy Pub Date : 2022-04-04 DOI:10.1089/mab.2022.0002

Hiroyuki Suzuki, Masaki Saito, Teizo Asano, Tomohiro Tanaka, Kaishi Kitamura, Yuma Kudo, M. Kaneko, Y. Kato

{"title":"C8Mab-3: An Anti-Mouse CCR8 Monoclonal Antibody for Immunocytochemistry.","authors":"Hiroyuki Suzuki, Masaki Saito, Teizo Asano, Tomohiro Tanaka, Kaishi Kitamura, Yuma Kudo, M. Kaneko, Y. Kato","doi":"10.1089/mab.2022.0002","DOIUrl":null,"url":null,"abstract":"The C-C motif chemokine receptor 8 (CCR8) is highly expressed in regulatory T cells. CCR8 is also expressed in many cancers and is associated with those progression. The development of monoclonal antibodies (mAbs) for CCR8 leads to cancer immunotherapy and elucidation of unknown mechanisms of CCR8-dependent cancer progression. In this study, we have developed an anti-mouse CCR8 (mCCR8) mAb (clone C8Mab-3, rat IgG1, kappa) using the Cell-Based Immunization and Screening (CBIS) method. We revealed that C8Mab-3 and its recombinant antibody (recC8Mab-3) bind to mCCR8-overexpressed Chinese hamster ovary (CHO)-K1 cells (CHO/mCCR8), but not to the parental CHO-K1 cells, in flow cytometry. In addition, C8Mab-3 and recC8Mab-3 reacted to P388 (a mouse lymphocyte-like cell) and J774-1 (a mouse macrophage-like cell), which express endogenous mCCR8. C8Mab-3 also detected exogenous and endogenous mCCR8 using immunocytochemistry. These results suggest that C8Mab-3, developed using the CBIS method, is useful for immunocytochemistry against exogenous and endogenous mCCR8.","PeriodicalId":53514,"journal":{"name":"Monoclonal Antibodies in Immunodiagnosis and Immunotherapy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Monoclonal Antibodies in Immunodiagnosis and Immunotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1089/mab.2022.0002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 9

Abstract

The C-C motif chemokine receptor 8 (CCR8) is highly expressed in regulatory T cells. CCR8 is also expressed in many cancers and is associated with those progression. The development of monoclonal antibodies (mAbs) for CCR8 leads to cancer immunotherapy and elucidation of unknown mechanisms of CCR8-dependent cancer progression. In this study, we have developed an anti-mouse CCR8 (mCCR8) mAb (clone C8Mab-3, rat IgG1, kappa) using the Cell-Based Immunization and Screening (CBIS) method. We revealed that C8Mab-3 and its recombinant antibody (recC8Mab-3) bind to mCCR8-overexpressed Chinese hamster ovary (CHO)-K1 cells (CHO/mCCR8), but not to the parental CHO-K1 cells, in flow cytometry. In addition, C8Mab-3 and recC8Mab-3 reacted to P388 (a mouse lymphocyte-like cell) and J774-1 (a mouse macrophage-like cell), which express endogenous mCCR8. C8Mab-3 also detected exogenous and endogenous mCCR8 using immunocytochemistry. These results suggest that C8Mab-3, developed using the CBIS method, is useful for immunocytochemistry against exogenous and endogenous mCCR8.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

C8Mab-3:免疫细胞化学抗小鼠CCR8单克隆抗体。

C-C基序趋化因子受体8（CCR8）在调节性T细胞中高度表达。CCR8也在许多癌症中表达，并与这些进展有关。针对CCR8的单克隆抗体（mAbs）的开发导致了癌症免疫疗法，并阐明了CCR8依赖性癌症进展的未知机制。在本研究中，我们使用基于细胞的免疫和筛选（CBIS）方法开发了一种抗小鼠CCR8（mCCR8）mAb（克隆C8Mab-3，大鼠IgG1，κ）。在流式细胞术中，我们发现C8Mab-3及其重组抗体（recC8Mab--3）与mCCR8过表达的中国仓鼠卵巢（CHO）-K1细胞（CHO/mCCR8）结合，但不与亲代CHO-K1细胞结合。此外，C8Mab3和recC8Mab-3与表达内源性mCCR8的P388（小鼠淋巴细胞样细胞）和J774-1（小鼠巨噬细胞样细胞）反应。C8Mab-3还通过免疫细胞化学检测外源性和内源性mCCR8。这些结果表明，使用CBIS方法开发的C8Mab-3可用于针对外源和内源性mCCR8的免疫细胞化学。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy Medicine-Immunology and Allergy

CiteScore

4.80

自引率

0.00%

发文量